Proficio Capital Partners LLC Purchases Shares of 38,669 Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Proficio Capital Partners LLC acquired a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 38,669 shares of the specialty pharmaceutical company’s stock, valued at approximately $4,762,000. Proficio Capital Partners LLC owned 0.06% of Jazz Pharmaceuticals at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Pacer Advisors Inc. increased its position in Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after purchasing an additional 278,465 shares during the last quarter. Cinctive Capital Management LP purchased a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter valued at $14,277,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Jazz Pharmaceuticals by 135.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after buying an additional 100,112 shares during the last quarter. Point72 Asset Management L.P. raised its position in shares of Jazz Pharmaceuticals by 47.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 268,783 shares of the specialty pharmaceutical company’s stock worth $29,945,000 after buying an additional 86,768 shares during the period. Finally, Two Sigma Advisers LP raised its position in shares of Jazz Pharmaceuticals by 393.0% in the 3rd quarter. Two Sigma Advisers LP now owns 106,000 shares of the specialty pharmaceutical company’s stock worth $11,809,000 after buying an additional 84,500 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on JAZZ shares. Robert W. Baird upped their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. TD Cowen dropped their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Piper Sandler restated an “overweight” rating and issued a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. Needham & Company LLC boosted their price objective on shares of Jazz Pharmaceuticals from $205.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, February 26th. Finally, Barclays reissued an “overweight” rating and issued a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $182.47.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $140.22 on Tuesday. The firm has a market cap of $8.52 billion, a price-to-earnings ratio of 19.75, a PEG ratio of 1.04 and a beta of 0.56. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The business’s 50 day moving average is $127.01 and its two-hundred day moving average is $119.37. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total transaction of $183,465.00. Following the completion of the transaction, the chief executive officer now directly owns 439,744 shares of the company’s stock, valued at $53,785,088.64. This trade represents a 0.34 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Patricia Carr sold 4,813 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the sale, the chief accounting officer now owns 8,237 shares in the company, valued at approximately $1,189,587.54. This trade represents a 36.88 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 18,113 shares of company stock worth $2,551,834. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.